LAPTM5 Antibody, FITC conjugated

1. These findings suggest that the inactivation of LAPTM5 may contribute to tumorigenesis in a subset of human cancers PMID: 27058622
2. Taken together, our results suggested that decreased LAPTM5 inhibited proliferation and viability, as well as induced G0/G1 cell cycle arrest possibly via deactivation of ERK1/2 and p38 in BCa cells PMID: 27922670
3. Insufficient expression of LAPTM5 may take part in the pathogenesis of systemic lupus erythematosus (SLE) and contribute to the severity of the disease, none of LAPTM5 polymorphisms contributes significantly to SLE susceptibility in a Chinese population. PMID: 25998573
4. The interaction of LAPTM5 with CD1e and their colocalization in antigen processing compartments both suggest that LAPTM5 might influence the role of CD1e in the presentation of lipid antigens. PMID: 22880058
5. LAPTM5 is a substrate of the ITCH-mediated degradation and its protein level is negatively regulated by ITCH PMID: 22009753
6. LAPTM5-mediated programmed cell death is closely associated with the spontaneous regression of neuroblastomas PMID: 19787053
7. LAPTM5 shows stage-specific expression during B cell differentiation. It may be involved in B cell malignancies. PMID: 12527926
8. results suggest that loss of E3 gene expression might be a crucial event during the progression of human MM PMID: 12886255

Show More

Hide All

HGNC: 29612

OMIM: 601476

KEGG: hsa:7805

STRING: 9606.ENSP00000294507

UniGene: Hs.371021